# Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

Study · id `cardio:ct-nct01499095` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01499095](<https://clinicaltrials.gov/study/NCT01499095>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01499095

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 811 participants.

## Technical summary

Registry record NCT01499095. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2015-04-23.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 811 participants (enrolled count; ClinicalTrials.gov record NCT01499095, source copy `cardio:ctgov-nct01499095-2022-03-23`, retrieved 2026-10-26)
- Start date: 2011-12 (registry gives no type) (ClinicalTrials.gov record NCT01499095, source copy `cardio:ctgov-nct01499095-2022-03-23`, retrieved 2026-10-26)
- Primary completion: 2013-04 (actual) (ClinicalTrials.gov record NCT01499095, source copy `cardio:ctgov-nct01499095-2022-03-23`, retrieved 2026-10-26)
- Completion: 2013-11 (actual) (ClinicalTrials.gov record NCT01499095, source copy `cardio:ctgov-nct01499095-2022-03-23`, retrieved 2026-10-26)
- Results first posted: 2015-04-23 (ClinicalTrials.gov record NCT01499095, source copy `cardio:ctgov-nct01499095-2022-03-23`, retrieved 2026-10-26)
- Countries: United States; Canada; Chile; Finland; France; Germany; Hungary; Mexico; Portugal; Romania; Russia; South Africa; Spain (ClinicalTrials.gov record NCT01499095, source copy `cardio:ctgov-nct01499095-2022-03-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01499095-2022-03-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
- Acronym: EDITION II
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Lantus (Insulin glargine)
- Intervention (Drug): HOE901-U300 (new formulation of insulin glargine)
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) (`cardio:pubmed-25193531`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension (`cardio:pubmed-26172084`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 14fbfcdd7b9003aa2c36f41791e913e1140546e48c3dc6fb12d257b5c30cd244
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
